Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-06-14
2005-06-14
Chang, Ceila (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S297000, C564S300000, C564S306000, C514S615000, C514S645000
Reexamination Certificate
active
06906104
ABSTRACT:
The present invention relates to compounds of formula (I):useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5720936 (1998-02-01), Wadsworth et al.
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5721131 (1998-02-01), Rudolph et al.
patent: 5744346 (1998-04-01), Chrysler et al.
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5850003 (1998-12-01), McLonlogue et al.
patent: 5877015 (1999-03-01), Hardy et al.
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 5912410 (1999-06-01), Cordell
patent: 5942400 (1999-08-01), Anderson et al.
patent: 6045829 (2000-04-01), Liversidge et al.
patent: 6191166 (2001-02-01), Audia et al.
patent: 2002/0192543 (2002-07-01), Schostarez et al.
patent: 2002/0192625 (2002-07-01), Schostarez et al.
patent: WO 98/22597 (1998-05-01), None
patent: WO 99/64001 (1999-12-01), None
patent: WO 00/03819 (2000-01-01), None
patent: WO 00/17369 (2000-03-01), None
patent: WO 00/47618 (2000-08-01), None
patent: WO 01/10387 (2001-02-01), None
patent: WO 01/23533 (2001-04-01), None
Lunney, Elizabeth et al. “Analyses of Ligand Binding in Five Endothiapepsin Crystal Complexes and Their Use in the Design and Evaluation of Novel Renin Inhibitors” Journal Medicinal Chemistry (1993), vol. 36, No. 24, pp. 3809-3820.
CAPLUS listing of Lunney et al, Accession No. 1993:662007, with RN structures.
U.S. Appl. No. 60/297,827, Schostarez, filed Jun. 13, 2001.
U.S. Appl. No. 60/333,084, Schostarez et al., filed Nov. 19, 2001.
Selkoe DJ., “The molecular pathology of Alzheimer's disease,” Neuron, Apr. 1991, 487-498.
Seubert et al., “Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids,” Sep. 1992, 325-327.
Luo et al., “Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation,” Nature Neuroscience, Mar. 2001, 231-232.
Hyafil et al., “In vitro and in vivo reversal of multidrug resistance by GF 120918, an acridonecarboxamide derivative,” Cancer Research, Oct. 1993, 4595-4602.
Dantzing, et al., “Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979,” Cancer Research, Sep. 1996, 4171-4179.
Hardy, John, “Framing beta-amyloid,” Nature Genetics, Jul. 1992, 233-234.
Vassar et al., Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE, Science, Oct. 1999, 735-741.
Yan et al., Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity, Nature Dec. 1999, 533-537.
Sihna et al., Purification and cloning of amyloid precursor protein beta-secretase from human brain, Nature, Dec. 1999, 537-540.
Lin et al., Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein, PNAS—Proceedings of the National Academy of Sciences, Feb. 2000, 1456-1460.
Kang et al., “The precursor of Alzheimer's disease amyloid !4 protein resembles a cell-surface receptor,” Nature, Feb. 1987, 733-736.
Citron et al., “Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production,” Nature, Dec. 1992, 672-674.
Games et al., “Alzheimer's-type neuropathology in transgenic mice overexpressig V717F beta-amyloid precursor protein, ” Nature, Feb. 1995, 523-527.
Hussain et al., Identification of a novel aspartic protease (Asp2) as beta-secretase, Molecular and Cellular Neurosciences, 1999, 419-427.
Pirttila et al., “Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probably Alzheimer's disease,” Neuroscience Letters, 1998, 21-24.
Chrusciel Robert Alan
Schostarez Heinrich Josef
Boehnen McDonnell
Chang Ceila
Coppins Janet L.
Hulbert & Berghoff LLP
Pharmacia & Upjohn Company
LandOfFree
Aminediols for the treatment of Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminediols for the treatment of Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminediols for the treatment of Alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3495918